Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Zynerba Pharmaceuticals (ZYNE) IPO Opens Up 29% Higher
August 5, 2015 10:54 AM EDTToday's IPO for Zynerba Pharmaceuticals (NASDAQ: ZYNE) opened for trading at $18 after pricing 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the... More
Zynerba Pharmaceuticals (ZYNE) Prices 3M Common Stock IPO at $14/Share
August 4, 2015 5:58 PM EDTZynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In... More
